The human understanding when it has once adopted an opinion (either as being the received opinion or as being agreeable to itself) draws all things else to support and agree with it. And though there be a greater number and weight of instances to be found on the other side, yet these it either neglects and despises, or else by some distinction sets aside and rejects, in order that by this great and pernicious predetermination the authority of its former conclusions may remain inviolate.
Sir Francis Bacon, Novum Organum 1620 Aphorism 46
Umbilical cord blood (UCB) cells are sometimes used as a source of haematopoietic cells for an allotransplant when bone marrow or blood cells from a suitable family or unrelated donor are lacking or inappropriate and/or when a transplant needs to be done quickly. Presently about 10% of unrelated-donor allotransplants for leukaemia use HLA-partially or -fully HLA-matched UCB units 1 about 60% of which are done in adults. 2 Several studies report UCB transplants and other alternative donor sources have comparable outcomes including HLA-matched unrelated donors and HLA-haplotype-matched relatives in adults. 3, 4 Whether this is so is controversial. 5 One of the main issues preventing wider use of UCB transplants in adults is concern over risks of slow, incomplete or un-sustained recovery of bone marrow function. This problem is usually attributed to relatively low numbers of stem and/or progenitor cells in UCB grafts compared with bone marrow or blood cell grafts. 3 Research has focused on trying to overcome this perceived problem using several approaches, such as combining two UCB units, co-infusion of mobilised blood cells from a third-party donor and ex vivo treatment and/or expansion of one or more UCB units. A comprehensive review of these approaches exceeds the scope of our commentary. Rather, our focus on an important current debate: are there convincing data outcomes of grafts of two UCB units are better than grafts of one UCB unit?
The notion of using two UCB units gained attention with a 2005 typescript reporting 21 adults receiving a pretransplant conditioning with fludarabine, cyclophosphamide and total body radiation, a graft of two units of HLA-disparate UCB followed by GvHD prophylaxis with cyclosporine and micophenolate mofetil. 6 This strategy resulted in long-term engraftment of one unit (termed the predominant unit) in all recipients, an engraftment rate seemingly higher than seen in historical controls receiving one UCB unit and also after different pretransplant conditioning and different GvHD prophylaxis. The investigators postulated a possible 'graft-versus-graft' whereby the non-dominant (subservient) unit would facilitate engraftment of the predominant unit by immune mechanisms. 6 (Graft-versus-graft may qualify with other jargon phrases such as engraftment syndrome 7 and autologous GvHD. 8 Time will tell). Whether the subservient UCB unit is really lost is controversial. 9 These investigators also postulated more potent allo-reactivity with a higher risk of GvHD and a lower risk of leukaemia relapse. 10 Since this report, use of two UCB units in adults has increased dramatically in recipients of conventional and reduced-intensity transplants for leukaemia and other disorders. 11, 12 However, recent data from the Center for Blood and Marrow Research indicate use of UCB transplants, especially in adults, has decreased substantially parallel to increasing use of HLA-haplotype-matched-related donors.
Whether claims of a benefit of using two UCB units in adults are credible is difficult to answer. There are no randomised, doubleblind trials in adults comparing outcomes of transplants using one versus two UCB units. Retrospective analyses comparing these approaches do not support more rapid, complete or/or sustained haematopoietic recovery or any other improved outcome using two versus one UCB units. [13] [14] [15] Two randomised trials in subjects o24 years reported no advantage of two versus one UCB grafts. 16, 17 More worrying is a reported increased risk of GvHD after grafts of two UCB units. [16] [17] [18] Based on these data, one wonders why many, even most, transplant experts recommend using two UCB units in adults`when an adequately dosed single UCB unit is not available'. 13 Could it be as Upton Sinclair said 'It is difficult to get a man to understand something when his salary depends on not understanding it'.
This expert-based but not evidence-based recommendation raises the question of what`adequately dosed' means. Often, and without strong scientific support, an`adequate' cell dose is defined as a total nucleated cell (TNC) dose 42.5 × E+7/kg recipient body weight. First, it is biologically unlikely an adequate or inadequate dose would be a binary. Second, other important determinants of engraftment are often not considered in defining an`adequate' dose such as genetic compatibility between donor and recipient, intensity of the conditioning regimen, posttransplant immune suppression and other variables. Also, apart from TNC, dose of CD34-positive cells and other indirect measurements of the quality of UCB units are likely important. For example, efficiency of engraftment of a UCB unit might be more highly correlated with other surrogates of haematopoietic stem or progenitor cell quantity such as numbers of colonyforming cells (CFU-C, BFU-E, CFU-GEMM, LTCIC and the like) or numbers of aldehyde dehydrogenase bright-positive cells. 19 Another important issue is that cell dose is calculated as a function of recipient body weight. This may make sense for some drugs but not for an infusion of haematopoietic stem and/or progenitor cells. The volume of distribution of hematopoietic progenitor and/or stem cells is low and relatively homogeneous in most adults and is poorly correlated with weight. Does doubling your weight alter your bone marrow mass, numbers of RBCs, granulocytes or platelets you produce and so on? Improbable.
For example, blood volume calculators, a parameter more likely to vary with weight than bone marrow mass, such as the Nadler or Gilcher equations routinely adjust for obesity discounting fat by a factor of about 25%. 20 Another example is age. A bone marrow cellularity of 50% is normal in persons 460 years old. These persons typically have normal bone marrow function and concentrations of blood cells comparable to younger persons with 80 or 90% bone marrow cellularity. The implication is one can have normal bone marrow function with fewer total bone marrow cells and probably fewer stem and progenitor cells. The latter point is evident from studies in young and old mice undergoing radiation and serial bone marrow or spleen cell transplants. Bone marrow from older mice with normal blood cell levels and normal bone marrow cellularity support fewer serial transfers than bone marrow from younger mice. [21] [22] [23] Several methods to calculate bone marrow mass, especially so-called red bone marrow mass are reported. 24 Data from mice exposed to high-dose radiation and transplanted with retrovirus-marked bone marrow cells indicate recovery of bone marrow function is from a succession of progenitor cells in the graft with different progenitor cells active at different intervals post-transplant and not from one or a few stem cells including grafts of UCB cells. [25] [26] [27] Similar data are reported in humans. 28, 29 The dynamics of bone marrow recovery is likely to be even more complex when the pretransplant conditioning regimen is less intensive. Endogenous haematopoietic stem and progenitor cells undoubtedly survive these reducedintensity regimens and in most instances will replace transplanted cells after an interval. 30 This concept has been nicely shown in parabiosed syngeneic mice. 31, 32 Moreover, some data suggest that an`adequate' cell dose may depend on diverse other variables, including the extent of HLA-and non-HLA-disparity, conditioning regimen, post-transplant immune suppression and other variables. 15 We are left with a paradox. Many studies report correlations between variables such as TNC dose, CD34-positive-cell dose based on body weight and transplant outcomes. How can this be? There are several potential explanations. First, these variables are likely surrogates for the cells which are responsible for short-and long-term bone marrow recovery post-transplant. As such they are subject to caveats regarding all surrogates including the need for internal and external validation. Their accuracy also needs to be tested by analysing their predictive value by generating a c-statistic in a receiver-operator characteristic curve and not by comparing outcomes of cohorts with different cutoff values. These analyses have not been done. Also, we need to potential avoid the error of assuming causal inference based on an association defined by statistical inference.
Another possible explanation is one well-known to experimental haematologist of a certain age: the spleen seeding efficiency or f factor. In radiated mice infused with syngeneic bone marrow or spleen cells, numbers of spleen colony-forming units (CFU-S) observed is related to numbers of pluripotent stem cells infused but also to their efficiency in forming CFU-S. [33] [34] [35] [36] Several variables contribute to this efficiency such as the bone from which the bone marrow cells were taken, their cell-cycle state and their likelihood of arriving in the spleen. The latter variable reflects cell loss such as trapping in the lung. The fundamental issue is that a stem or pluripotent cell which never arrives at a site able to support haematopoiesis (nowadays termed the stem cell niche) cannot contribute to haematopoiesis. Because the size of some organs and tissues (unlike the bone marrow) increases with increasing body mass (not weight), identical numbers of stem or pluripotent haematopoietic stem cells infused into a larger person with a low f factor. This could, at least in part, explain a correlation between UCB cell dose and weight, although mass or lung volume would be a better parameter than weight.
Another confounder is which transplant endpoint(s) is relevant. Namely, what is an`adequate' dose for what outcome? Is it incidence rate or speed of engraftment, frequency of sustained bone marrow recovery (which may or may not derive from the transplanted cells depending on the pretransplant conditioning regimen, genetic compatibility and so on), non-relapse mortality, incidence and/or severity of GvHD, cumulative incidence of leukaemia relapse, leukaemia-free survival or survival? For example, when the endpoint is cumulative incidence of relapse is not the biology of the leukaemia likely to be far more important than numbers of TNCs per body weight in the graft? And these outcomes may be confounded. 37 One can of course argue TNC dose per body weight correlates with everything: engraftment capacity, transplant-related mortality, GvHD-inducing capacity, anti-leukaemia activity and the like. However, this seems far-fetched even for the most enthusiastic advocate of the import of cell dose. Can any variable be an effective surrogate for some many diverse biological activities? Clearly, we need to stop and re-think.
Although not the subject of this commentary we should briefly mention alternate approaches to the problem of graft size in adults. Several are proposed such as treating UCB cells in vitro to increase numbers of CD34-positive cells and/or engraftment efficiency by more effective homing to appropriate bone marrow niches (the f factor discussed above). Examples include fucosylation of selectin ligands on UCB cells, culture with NOTCH-ligand or co-mesenchymal cells, hyperbaric oxygen and so on, adding HLA-haplotype-matched blood or bone marrow cells to the UCB cell graft, giving an intentionally HLA-mismatched UCB unit along with an HLA-matched unit to increase antileukaemia efficacy and others. Many of these approaches were recently reviewed. 38, 39 Proof of efficacy of these interventions requires validation in a randomised trial.
Returning to our starting question, there seems little or no theoretical, experimental or clinical data supporting using two versus one unit of UCB cells for a graft. Because there is additional risk and considerable expense involved in using two UCB cell units rather than one the burden of proof of additional benefit without increased risk is asymmetrical and rests with proponents of this approach. A randomised, double-blind trial is obviously needed. Unfortunately, this seems unlikely to be done. Until there are convincing data, we favour using a single UCB unit.
Do we think this perspective will change clinical practice? Unlikely. We are reminded of a quote from Samuel Butler. 40 He that complies against his will Is of his own opinion still Which he may adhere to, yet disown, For reasons to himself best known At least we tried.
